Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)

The U.S. Department of Health and Human Services, through the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases, forecasts support for the Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes program under opportunity number RFA-DK-28-116. The opportunity is a discretionary federal cooperative agreement in the Health funding activity category and is associated with Assistance Listing 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research. NIDDK has supported major type 1 diabetes research consortia spanning basic, translational, and clinical research. These consortia have generated large longitudinal and multimodal datasets through standardized protocols and coordinated studies focused on different organs, disease stages, biological processes, and clinical outcomes. The purpose of the forecasted opportunity is to use recent advances in artificial intelligence to integrate complementary type 1 diabetes datasets and accelerate precision medicine. NIDDK intends to support a coordinated, milestone-driven research project that combines multimodal human pancreas and clinical datasets to investigate how biological processes interact during the development and progression of type 1 diabetes. The work is expected to generate new insights into type 1 diabetes biology, improve understanding of different forms and stages of the disease, identify biomarkers, and inform approaches to disease prevention, intervention, and treatment. The planned project will develop and test advanced multimodal artificial intelligence models as part of the research effort. It will also develop AI-enabled research workflows, methods for integrating data, and privacy-preserving synthetic datasets. The forecast emphasizes the opportunity created by combining resources from multiple research consortia rather than analyzing individual datasets in isolation. The source does not provide a detailed budget by allowable cost category, award floor, award ceiling, indirect cost limitation, subaward limitation, or other specific spending restriction. Estimated total program funding is $5,000,000, with one award expected. No cost sharing or matching is required. The funding instrument is a cooperative agreement, and clinical trials are not allowed under this opportunity. Eligible applicants include state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities and Indian housing authorities, federally recognized Native American tribal governments, other Native American tribal organizations and governments, public and state controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status other than institutions of higher education, for-profit organizations other than small businesses, and small businesses. Additional eligible applicants include eligible agencies of the federal government, U.S. territories or possessions, faith-based or community-based organizations, regional organizations, and non-domestic entities or foreign institutions. The source does not impose a specific U.S. state restriction. This record is a forecast rather than an open funding announcement. The opportunity was forecast on August 20, 2026 and last updated on August 20, 2026. The estimated posting date is December 1, 2026, so applications are not yet being accepted based on the information provided. The estimated application due date is February 10, 2027. The provided forecast does not identify a letter of intent, concept paper, pre-proposal, notice of intent, initial application, or other pre-application gating requirement. It also does not provide application forms, required narratives or uploads, submission questions, evaluation criteria, review criteria, or detailed submission mechanics. Applicants therefore will need to consult the future posted notice for those requirements when they become available. The estimated award date is November 1, 2027, and the estimated project start date is December 1, 2027, with fiscal year 2028 identified for the opportunity. The forecast does not state a period of performance or indicate that the opportunity recurs annually, biennially, quarterly, or according to another recurring schedule. Because no recurrence language is provided, the opportunity is treated as non-recurring based strictly on the available source. Program questions may be directed to the Division of Diabetes, Endocrinology and Metabolic Diseases at NIDDK by email at NIDDK_DEM@nih.gov. No individual grantor contact name or telephone number is provided in the source.

Emphasize a coordinated, milestone-driven research approach that integrates multimodal human pancreas and clinical datasets. Demonstrate how advanced multimodal AI models and AI-enabled workflows can reveal interactions across tissues, disease stages, and biological levels, generate insights into T1D biology, identify biomarkers, and inform prevention, intervention, or treatment. Address data integration and privacy-preserving synthetic data where relevant to the proposed research.